Abvc Biopharma (ABVC) Other Non Operating Income (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Other Non Operating Income came in at -$51156.0 in Q1 2026, down 599.47% YoY from $10242.0 in Q1 2025, and up 43.93% on a QoQ basis from -$91229.0 in Q4 2025.
Abvc Biopharma (ABVC) Other Non Operating Income (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 13 years of Other Non Operating Income data on file, last reported at -$51156.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 599.47% year-over-year to -$51156.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118790.0 (down 356.07% YoY) and the FY2025 annual result came in at -$77546.0, down 157.68% from the prior year.
- Other Non Operating Income climbed to -$51156.0 in Q1 2026, from -$91229.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $136148.0 in Q2 2025 to a low of -$261063.0 in Q4 2022.
- A 5-year average of -$11352.3 and a median of $3067.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 4551.84% — and 2023, when it plunged 14057.63%.
- Tracing ABVC's Other Non Operating Income over 5 years: stood at -$261063.0 in 2022, then surged by 130.0% to $78315.0 in 2023, then jumped by 38.11% to $108159.0 in 2024, then plunged by 184.35% to -$91229.0 in 2025, then surged by 43.93% to -$51156.0 in 2026.
- The last three Other Non Operating Income figures came in at -$51156.0 (Q1 2026), -$91229.0 (Q4 2025), and -$112553.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,378.00 |
| Mar 31, 2026 | -51,156.00 |
| Dec 31, 2025 | -91,229.00 |
| Sep 30, 2025 | -112,553.00 |
| Jun 30, 2025 | 136,148.00 |
| Mar 31, 2025 | 10,242.00 |
| Dec 31, 2024 | 108,159.00 |
| Sep 30, 2024 | -7,136.00 |
| Jun 30, 2024 | -64,875.00 |
| Mar 31, 2024 | 19,485.00 |
| Dec 31, 2023 | 78,315.00 |
| Sep 30, 2023 | -25,059.00 |
| Jun 30, 2023 | 3,528.00 |
| Mar 31, 2023 | 3,067.00 |
| Dec 31, 2022 | -261,063.00 |
| Sep 30, 2022 | -177.00 |
| Jun 30, 2022 | 17,076.00 |
| Mar 31, 2022 | 44,239.00 |
| Dec 31, 2021 | 488,280.00 |
| Sep 30, 2021 | 8,643.00 |